These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 11401940)

  • 1. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).
    Bloomfield Rubins H; Davenport J; Babikian V; Brass LM; Collins D; Wexler L; Wagner S; Papademetriou V; Rutan G; Robins SJ;
    Circulation; 2001 Jun; 103(23):2828-33. PubMed ID: 11401940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
    JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
    N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
    Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H;
    Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.
    Rubins HB; Robins SJ; Iwane MK; Boden WE; Elam MB; Fye CL; Gordon DJ; Schaefer EJ; Schectman G; Wittes JT
    Am J Cardiol; 1993 Jan; 71(1):45-52. PubMed ID: 8420235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.
    Brousseau ME; O'Connor JJ; Ordovas JM; Collins D; Otvos JD; Massov T; McNamara JR; Rubins HB; Robins SJ; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1148-54. PubMed ID: 12117730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
    Boden WE
    Am J Cardiol; 2000 Dec; 86(12A):19L-22L. PubMed ID: 11374850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD
    Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).
    Rubins HB; Robins SJ; Collins D; Nelson DB; Elam MB; Schaefer EJ; Faas FH; Anderson JW
    Arch Intern Med; 2002 Dec 9-23; 162(22):2597-604. PubMed ID: 12456232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
    Manninen V; Tenkanen L; Koskinen P; Huttunen JK; Mänttäri M; Heinonen OP; Frick MH
    Circulation; 1992 Jan; 85(1):37-45. PubMed ID: 1728471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).
    Robins SJ; Rubins HB; Faas FH; Schaefer EJ; Elam MB; Anderson JW; Collins D;
    Diabetes Care; 2003 May; 26(5):1513-7. PubMed ID: 12716814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.
    Tonelli M; Collins D; Robins S; Bloomfield H; Curhan GC;
    Kidney Int; 2004 Sep; 66(3):1123-30. PubMed ID: 15327407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease: results of the VA-HIT study].
    Scheen AJ
    Rev Med Liege; 1999 Sep; 54(9):773-5. PubMed ID: 10589275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.
    Frick MH; Syvänne M; Nieminen MS; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Taskinen MR
    Circulation; 1997 Oct; 96(7):2137-43. PubMed ID: 9337181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
    N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
    Otvos JD; Collins D; Freedman DS; Shalaurova I; Schaefer EJ; McNamara JR; Bloomfield HE; Robins SJ
    Circulation; 2006 Mar; 113(12):1556-63. PubMed ID: 16534013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?
    Rizos E; Mikhailidis DP
    Cardiovasc Res; 2001 Nov; 52(2):199-207. PubMed ID: 11684067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial.
    Adabag AS; Mithani S; Al Aloul B; Collins D; Bertog S; Bloomfield HE;
    Am Heart J; 2009 May; 157(5):913-8. PubMed ID: 19376321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.